Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial
Description
CONCLUSION: Leflunomide, added to the SOC treatment for COVID-19, was safe and well tolerated but had no major impact on clinical outcomes. It may shorten the time of oxygen dependence by 1 day and thereby improve TTCI/hospital discharge in
